13 June 2019 - Servier has announced that its non-Hodgkin B-cell lymphoma drug, Pixuvri (pixantrone), has been granted the conversion of the conditional approval into standard marketing authorisation as a single agent.

The indication noted is for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.

The company also announced that to satisfy requirements of the conditional authorisation, a further Phase III clinical study, PIX306, was completed to provide additional efficacy data to confirm the benefit of the treatment in patients that had received prior treatment regimens containing rituximab.

Read Pharma Times article